DalCor Pharmaceuticals is a biopharmaceutical company dedicated to tackling cardiovascular disease, a significant global healthcare challenge. Their mission is to provide dalcetrapib, the first pharmacogenetic precision medicine for cardiovascular disease, specifically targeting patients with the AA genotype at the rs1967309 location in the ADCY9 gene. Dalcetrapib is currently undergoing evaluation in the Dal-GenE-2 DAL-302 Phase 3 clinical trial, aiming to reduce fatal and non-fatal myocardial infarction in 2000 patients with post-acute coronary syndrome who possess the ADCY9 AA genotype.
With a strong focus on precision medicine, DalCor Pharmaceuticals has administered dalcetrapib to over 15,000 patients worldwide, demonstrating a good safety and tolerability profile. Their groundbreaking research and clinical trials have shown promising results, including a 21% relative risk reduction in fatal and non-fatal myocardial infarction in a diverse patient population across 34 countries. DalCor Pharmaceuticals is committed to advancing precision medicine for cardiovascular diseases and improving patient outcomes.
Generated from the website